In a recent internal study, Waisman Biomanufacturing was able to demonstrate comparability for a new manufacturing platform combining bioreactors and microcarriers using mesenchymal stromal cells.

Researchers seeking reliable ways to recapitulate physiological conditions are turning to spheroids and other 3D object, seeking ways to mass produce these 3D models for various applications.

The combination CRISPR screening and bulk spheroid production is of growing interest for those who want to study cancer and other diseases in a more physiologically relevant setting with less reliance on model animals.

Scientists are working to discover new and effective ways precision medicine can prevent, diagnose, and treat diseases such as cancer.

Investigate important considerations for working with three different stem cell types: mesenchymal stem/stromal cells, induced pluripotent stem cells, and neural stem cells.

The cryopreservation process maintains the structural integrity of living cells, but what other information is crucial for manufacturers when considering cryopreservation and its impact on cell-based therapies?

There are some pointed questions that manufacturers need to ask their suppliers before stocking or restocking serums in their lab. Here are six they can start with.

Sustainable solutions are being explored by manufacturers to combat waste during biomedical research and reduce the environmental impact of labs.

Biomanufacturers looking to take advantage of the ongoing biomedical revolution and new treatments can benefit from platform solutions utilized in scaling-up adherent cell cultures.

Learn how CDMOs fill the gap between cutting-edge science and the commercial sector of cell-and-gene therapeutics by partnering with the best technology providers to maximize the manufacturing process.

During each Cell & Gene Live, our audience can submit real-time questions for our expert panelists. Watch and listen as Michael Blackton and John Lee provide detailed, insightful responses to our audience questions on everything from how changing from a lab-based adherent protocol to suspension scalable protocol improved the cell product to whether a container with lesser cells, identical cell density, and composition be used for establishing stability for cell therapy products, and much more.

During Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Michael Blackton and John Lee provided detail on how successful comparability studies are designed and executed. They covered the in-process and release testing requirements, as well as the common and uncommon pit falls that have been encountered.

For cell-based products, donor-to-donor variability is the primary source of complexity associated with establishing product comparability. In this segment of Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Michael Blackton and John Lee cover why donor-to-donor variability is an on-going challenge and potential solutions.

Here, during this segment of Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Michael Blackton and John Lee highlight the various ways to demonstrate our understanding of how the process influences the product, as well as how the product’s structure influences its clinical function.

As a therapy proceeds through Phases I / II and into Phase III clinical trials, the comparability burden increases. As the body of knowledge increases, the comparability burden evolves. Some tests may be removed while others are added, and assumptions may change with data. In this segment of Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Michael Blackton and John Lee break down the comparability requirements from early- to late-stage programs.

During this Cell & Gene Live, "Scaling Cell Therapies Part 2: Establishing Comparability in Manufacturing," Cell & Gene's Chief Editor, Erin Harris, Michael Blackton, former SVP Cell Therapy Manufacturing at Nurix Therapeutics, and John Lee, SVP, Head of Cell Therapy at Center for Breakthrough Medicines, talk through the CGT sector's greatest struggles with comparability. Indeed in this segment, Blackton and Lee cover the sector's biggest challenges to date from the need to truly understand the product to precise analytics and eliminating silos, and more.

In this video our application scientists walk you through common research goals and the most suitable 3D cell culture solutions for each.

There are many harvesting options depending on the cell line and application. In this video we discuss some tips and tricks for harvesting cells.

The Corning® Matribot® bioprinter uses a revolutionary cooling syringe printhead technology that allows you to dispense 3D droplets or droplet arrays for organoid applications.

With gas-permeable film, this closed system offers more surface area within a compact footprint. Watch this short video to learn more.

We visit the MEARY Center to see how they produce new cells and new gene therapy drugs to treat patients suffering from autoimmune, hematological, and cardiac diseases, and so much more.

In the complex world of cell and gene therapy, having a seasoned partner to guide you through uncharted production territory is critical to success.

Corning’s Field Applications Specialists work with scientists like you to overcome complex manufacturing challenges and streamline the path to production.

The Ascent FBR System’s novel mesh substrate intensifies cell growth surface area to produce high cell yields more efficiently.

When you need a reliable path from research to bioprocessing try efficient tools like the Corning® HYPERFlask® cell culture vessel.